BORONATED METALLOPORPHYRINS - A NOVEL-APPROACH TO THE DIAGNOSIS AND TREATMENT OF CANCER USING CONTRAST-ENHANCED MR IMAGING AND NEUTRON-CAPTURE THERAPY

被引：23

作者：

HUANG, LR ^{[1
]}

STRAUBINGER, RM ^{[1
]}

KAHL, SB ^{[1
]}

KOO, MS ^{[1
]}

ALLETTO, JJ ^{[1
]}

MAZURCHUK, R ^{[1
]}

CHAU, RI ^{[1
]}

THAMER, SL ^{[1
]}

FIEL, RJ ^{[1
]}

机构：

[1] ROSWELL PK CANC INST,DEPT BIOPHYS,ELM & CARLTON ST,BUFFALO,NY 14263

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 02期

关键词：

BORON; CONTRAST ENHANCEMENT; CONTRAST MEDIA; MANGANESE; NEOPLASMS; MR; THERAPY; PORPHYRIN; UTILIZATION;

D O I：

10.1002/jmri.1880030210

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Porphyrins are a unique class of metal chelating agents that have shown specific affinity for neoplasms. The water-soluble free-base derivative, tetrakiscarborane carboxylate ester of 2,4- (alpha,beta-dihydroxyethyl) deuteroporphyrin IX (BOPP), an agent designed for neutron capture therapy, has previously demonstrated selective localization and retention in a C6 murine glioma. In the present work, the authors demonstrate that the manganese chelate of BOPP also selectively localizes in a rat 9L gliosarcoma and preferentially enhances the tumor-normal brain contrast of T1-weighted images for at least 92 hours. The data indicate a maximal enhancement of contrast between tumor and normal brain at 24 hours after injection, compared with 5 minutes for manganese (III) tetraphenylporphine sulfonate (TPPS4). The results also indicate that Mn-BOPP may have a slower uptake in the 9L glioma than Mn-TPPS4 but a longer retention in the tumor. Mn-BOPP is unique in that it represents, to the authors' knowledge, the first example of a single agent that can enhance contrast between tumor and normal tissue and be potentially effective as an agent for boron neutron capture therapy.

引用

页码：351 / 356

页数：6

共 30 条

[21]

Loach PA, Calvin M, Oxidation states of manganese hematoporphyrin IX in aqueous solution, Biochemistry, 2, pp. 361-371, (1963)

[22]

Benda P, Someda K, Messer J, Sweet WH, Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture, J Neurosurg, 34, pp. 310-323, (1971)

[23]

Baker M, Hoshino T, Gurcay O, Et al., Development of an animal brain tumor model and its response to therapy with 1,3‐bis(2‐chloro‐ethyl)‐1‐nitrosourea, Cancer Res, 33, pp. 976-986, (1973)

[24]

Megnin F, Faustino P, Lyon R, Lelkes P, Cohen J, Studies on the mechanism of selective retention ofporphyrins and metalloporphyrins by cancer cells, Biochem Biophys Acta, 929, pp. 173-181, (1987)

[25]

Fiel RJ, Mark E, Button T, Gilani S, Musser D, Mechanism of the localization of manganese (III) mesotetra(4‐sulfonatephenyl)‐porphine in mice bearing L1210 tumors, Cancer Res, 40, pp. 23-32, (1988)

[26]

Kaye AH, Photoradiation therapy of malignant brain gliomas: current concepts and further applications, Malignant cerebral glioma, 1990, pp. 189-202, (1990)

[27]

Button TM, Fiel RJ, Isointense model for the evaluation of tumor‐specific MRI contrast agents, Magn Reson Imaging, 6, pp. 275-280, (1988)

[28]

Inoue T, Fukui M, Nishio S, Kitamura K, Nagara H, Hyperosmotic blood‐brain barrier disruption in brains of rats with an intracerebrally transplanted RG‐C6 tumor, J Neurosurg, 66, pp. 256-263, (1987)

[29]

Warnke PC, Blasberg RG, Groothuis DR, The effect of hyperosmotic blood‐brain barrier disruption on blood‐to‐tissue transport in NU‐induced gliomas, Ann Neurol, 22, pp. 300-305, (1987)

[30]

Kabalka GW, Cheng G, Bendel P, Micca PL, Slatkin DN, In vivo boron‐11 MRI and MRS using (B24H22S2)4‐ in the rat, Magn Reson Imaging, 9, pp. 969-973, (1991)

← 1 2 3 →